In April the Committee for Medicinal Products for Human Use of the European Medicines Agency endorsed a gene therapy treatment called Strimvelis[131][132] and the European Commission approved it in June.[133] This treats children born with ADA-SCID and who have no functioning immune system â€” sometimes called the "bubble baby" disease. This was the second gene therapy treatment to be approved in Europe.[134]